Last reviewed · How we verify
Genotype Guided PPI Dosing
Genotype-guided PPI dosing optimizes proton pump inhibitor therapy by tailoring doses based on individual CYP2C19 metabolizer status to improve efficacy and safety.
Genotype-guided PPI dosing optimizes proton pump inhibitor therapy by tailoring doses based on individual CYP2C19 metabolizer status to improve efficacy and safety. Used for Gastroesophageal reflux disease (GERD) — genotype-guided dosing, Peptic ulcer disease — genotype-guided dosing, Acid-related disorders requiring PPI therapy — genotype-guided dosing.
At a glance
| Generic name | Genotype Guided PPI Dosing |
|---|---|
| Also known as | Prilosec, Nexium, Prevacid, Proton Pump Inhibitor |
| Sponsor | Nemours Children's Clinic |
| Drug class | Proton pump inhibitor (PPI) — dosing optimization strategy |
| Target | CYP2C19 (cytochrome P450 2C19 enzyme variants) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This is a pharmacogenomic dosing strategy rather than a novel drug. It uses genetic testing of CYP2C19 variants to classify patients as poor, intermediate, extensive, or ultra-rapid metabolizers, then adjusts PPI doses accordingly. Poor metabolizers require lower doses to avoid toxicity, while ultra-rapid metabolizers may need higher doses for therapeutic effect.
Approved indications
- Gastroesophageal reflux disease (GERD) — genotype-guided dosing
- Peptic ulcer disease — genotype-guided dosing
- Acid-related disorders requiring PPI therapy — genotype-guided dosing
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
Key clinical trials
- Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing (NA)
- Implementation of PPI Medication PGX Testing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genotype Guided PPI Dosing CI brief — competitive landscape report
- Genotype Guided PPI Dosing updates RSS · CI watch RSS
- Nemours Children's Clinic portfolio CI